Compare Stocks: XNCR, LGND, ORKA, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$18.27 -1.9%	$16.69	$1.33 ▼ $24.28	$5.79B	0.66	4.52 million shs	2.43 million shs
LGND Ligand Pharmaceuticals	$300.14 -0.8%	$284.75	$137.14 ▼ $326.63	$6.06B	1.13	309,811 shs	391,885 shs
ORKA Oruka Therapeutics	$98.42 +1.3%	$81.78	$12.84 ▼ $99.80	$5.86B	-0.34	867,166 shs	717,345 shs
XNCR Xencor	$20.00 +0.8%	$15.52	$6.92 ▼ $21.96	$1.47B	0.85	1.08 million shs	996,652 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-1.88%	-2.19%	-0.49%	+80.53%	+1,177.62%
LGND Ligand Pharmaceuticals	-0.80%	+1.30%	-6.04%	+35.56%	+110.77%
ORKA Oruka Therapeutics	+1.27%	+0.57%	+16.47%	+52.38%	+593.59%
XNCR Xencor	+0.81%	-6.93%	+27.63%	+55.52%	+167.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$18.27 -1.9%	$16.69	$1.33 ▼ $24.28	$5.79B	0.66	4.52 million shs	2.43 million shs
LGND Ligand Pharmaceuticals	$300.14 -0.8%	$284.75	$137.14 ▼ $326.63	$6.06B	1.13	309,811 shs	391,885 shs
ORKA Oruka Therapeutics	$98.42 +1.3%	$81.78	$12.84 ▼ $99.80	$5.86B	-0.34	867,166 shs	717,345 shs
XNCR Xencor	$20.00 +0.8%	$15.52	$6.92 ▼ $21.96	$1.47B	0.85	1.08 million shs	996,652 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-1.88%	-2.19%	-0.49%	+80.53%	+1,177.62%
LGND Ligand Pharmaceuticals	-0.80%	+1.30%	-6.04%	+35.56%	+110.77%
ORKA Oruka Therapeutics	+1.27%	+0.57%	+16.47%	+52.38%	+593.59%
XNCR Xencor	+0.81%	-6.93%	+27.63%	+55.52%	+167.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.64	Moderate Buy	$21.64	18.43% Upside
LGND Ligand Pharmaceuticals	2.88	Moderate Buy	$335.86	11.90% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$134.30	36.46% Upside
XNCR Xencor	2.44	Hold	$24.86	24.29% Upside

Current Analyst Ratings Breakdown

Latest XNCR, LGND, ORKA, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$289.00 ➝ $358.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
8/3/2026	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$285.00 ➝ $326.00
8/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
7/30/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00
7/21/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$387.00
7/20/2026	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$12.00 ➝ $21.00
7/15/2026	ORKA Oruka Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$262.00 ➝ $340.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
LGND Ligand Pharmaceuticals	$290.54M	20.70	$7.79 per share	38.53	$51.68 per share	5.81
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
XNCR Xencor	$125.58M	11.81	N/A	N/A	$8.90 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$124.55M	-$0.93	N/A	N/A	N/A	N/A	-35.31%	-29.49%	8/11/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$7.37	40.72	34.34	2.79	55.95%	16.19%	11.13%	N/A
ORKA Oruka Therapeutics	-$105.43M	-$1.94	N/A	N/A	N/A	N/A	-26.16%	-25.00%	8/10/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.29	N/A	N/A	N/A	-155.59%	-27.58%	-19.75%	N/A

Latest XNCR, LGND, ORKA, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.95	$2.37	+$0.42	$2.22	$60.87 million	$63.69 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
5/13/2026	Q1 2026	ORKA Oruka Therapeutics	-$0.52	-$0.48	+$0.04	-$0.48	N/A	N/A
5/11/2026	Q1 2026	ERAS Erasca	-$0.1150	-$0.60	-$0.4850	-$0.60	N/A	N/A
5/7/2026	Q1 2026	LGND Ligand Pharmaceuticals	$1.84	$1.63	-$0.21	-$0.67	$59.10 million	$51.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	9.52	9.52
LGND Ligand Pharmaceuticals	0.45	21.28	20.95
ORKA Oruka Therapeutics	N/A	23.76	23.76
XNCR Xencor	N/A	6.57	6.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
LGND Ligand Pharmaceuticals	91.28%
ORKA Oruka Therapeutics	56.44%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.20%
LGND Ligand Pharmaceuticals	5.60%
ORKA Oruka Therapeutics	23.49%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	310.98 million	266.83 million	Optionable
LGND Ligand Pharmaceuticals	80	20.04 million	18.92 million	Optionable
ORKA Oruka Therapeutics	N/A	60.31 million	46.15 million	N/A
XNCR Xencor	280	74.14 million	70.38 million	Optionable

XNCR, LGND, ORKA, and ERAS Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Hold" by Brokerages

4 hours ago | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

4 hours ago | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

August 7 at 1:34 AM | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6 at 11:48 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6 at 10:19 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6 at 8:23 AM | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5 at 6:26 PM | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5 at 6:10 PM | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush

August 1, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

July 30, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

July 30, 2026 | marketbeat.com

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

July 29, 2026 | finance.yahoo.com

Xencor (XNCR) Expected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR

July 28, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?

July 22, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

July 21, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume - Here's Why

July 20, 2026 | marketbeat.com

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

July 20, 2026 | zacks.com

Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

July 19, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XNCR, LGND, ORKA, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$18.27 -0.35 (-1.88%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$18.30 +0.03 (+0.16%)

As of 04:00 AM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ligand Pharmaceuticals NASDAQ:LGND

$300.14 -2.43 (-0.80%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$300.89 +0.75 (+0.25%)

As of 04:17 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Oruka Therapeutics NASDAQ:ORKA

$98.42 +1.23 (+1.27%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$98.75 +0.33 (+0.34%)

As of 05:48 AM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Xencor NASDAQ:XNCR

$20.00 +0.16 (+0.81%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$19.85 -0.15 (-0.75%)

As of 05:35 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XNCR, LGND, ORKA, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XNCR, LGND, ORKA, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XNCR, LGND, ORKA, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XNCR, LGND, ORKA, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

Ligand Pharmaceuticals NASDAQ:LGND

Oruka Therapeutics NASDAQ:ORKA

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XNCR, LGND, ORKA, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XNCR, LGND, ORKA, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XNCR, LGND, ORKA, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XNCR, LGND, ORKA, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

Ligand Pharmaceuticals NASDAQ:LGND

Oruka Therapeutics NASDAQ:ORKA

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools